Journal of Contemporary Psychotherapy

, Volume 46, Issue 1, pp 1–13 | Cite as

Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients

Original Paper
  • 496 Downloads

Abstract

Because the epidemic dispensing of psychiatric drugs is based on misinformation, it is important for all health professionals, consumers, and most citizens (including patients and their family members) to have a more rational understanding of how psychiatric drugs actually “work.” Instead of enforcing authoritarian “medication compliance” in obedience to the prescriber’s orders, informed therapists and healthcare providers have an ethical duty to provide scientific information about the real effects of psychiatric drugs. Instead of naively accepting whatever the doctor prescribes to them, consumers need to educate themselves about all medications, but especially about psychiatric ones, which are consistently misrepresented and oversold. This review focuses on three principles of rational psychopharmacology. The first is the brain-disabling principle, which states that all psychoactive substances work by causing dysfunctions of the brain and mind. It further observes that no psychiatric drugs work by improving or correcting biochemical imbalances or any other presumed biological malfunctions. The second principle is intoxication anosognosia (medication spellbinding) which states that all psychoactive substances tend to cause a subjective over-estimation of their positive effects while masking their harmful ones, sometimes resulting in extremely harmful behaviors such as mania, violence and suicide. The third principle is chronic brain impairment (CBI)—that exposure to psychoactive substances, especially long-term, results in impairments of the brain or mind that can become persistent or permanent, including atrophy (shrinkage) of brain tissue. Not only are psychiatric drugs likely to do more harm than good, there are more effective and infinitely safer proven psychosocial approaches for treating the whole spectrum of “psychiatric disorders” from “ADHD” and “major depressive disorder” to “schizophrenia.”

Keywords

Psychopharmacology Psychiatric drugs Adverse psychiatric drug effects Psychosocial alternatives to psychiatric drugs Ineffectiveness of psychiatric drugs Critical analysis of psychiatric medication 

References

  1. Abramson, J. (2005). Overdo$ed America. New York: Harper Perennial.Google Scholar
  2. Adderall XR (2015, April). Full Prescribing Information. Retrieved April 11, 2015 from http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF.
  3. Adityanjee., Munshi, K. R., & Thampy, A. (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical neuropharmacology, 28(1), 38–49.PubMedCrossRefGoogle Scholar
  4. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association.Google Scholar
  5. Angell, M. (2004). The truth about drug companies: How they deceive us and what to do about it. New York: Harper Random House.Google Scholar
  6. Antonuccio, D., Danton, W., DeNelsky, G., Greenberg, R., & Gordon, J. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3–14.PubMedCrossRefGoogle Scholar
  7. Ballenger, J. (1995). Benzodiazepines. In A. Schatzberg & C. Nemeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology (pp. 215–230). Washington, DC: American Psychiatric Press.Google Scholar
  8. Barnhart, W., Makela, E., & Latocha, M. (2004). SSRI-induced apathy syndrome: A clinical review. Journal of Psychiatric Practice, 10, 196–199.PubMedCrossRefGoogle Scholar
  9. Baughman, F, Jr, & Hovey, C. (2006). The ADHD Fraud: How psychiatry makes “patients” of normal children. Victoria, BC: Trafford Publishing.Google Scholar
  10. Bockoven, S. (1963). Moral treatment in American psychiatry. New York: Springer Publishing Company.CrossRefGoogle Scholar
  11. Breggin, P. (1980). Brain-disabling therapies. In E. Valenstein (Ed.), The psychosurgery debate: Scientific, legal and ethical perspectives (pp. 467–505). San Francisco: Freeman.Google Scholar
  12. Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer.Google Scholar
  13. Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology, implications. Journal of Mind and Behavior, 11, 425–464.Google Scholar
  14. Breggin, P. (1991). Toxic Psychiatry: Why therapy, empathy and love must replace the drugs, electroshock, and biochemical theories of the ‘new psychiatry’. New York: St. Martin’s Press.Google Scholar
  15. Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. Brain and Cognition, 23, 8–27.PubMedCrossRefGoogle Scholar
  16. Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s spontaneous reporting system. Journal of Mind and Behavior, 19, 21–50.Google Scholar
  17. Breggin, P. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk and Safety in Medicine, 12, 3–35.Google Scholar
  18. Breggin, P. (2003/2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk and Safety in Medicine, 16, 31–49.Google Scholar
  19. Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15.Google Scholar
  20. Breggin, P. (2008a). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the psychopharmaceutical complex (2nd ed.). New York: Springer.Google Scholar
  21. Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide, and crime. New York: St. Martin’s Press.Google Scholar
  22. Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200.Google Scholar
  23. Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescribers, therapists, patients and their families. New York: Springer.Google Scholar
  24. Breggin, P. (2014a). The rights of children and parents in regard to children receiving psychiatric drugs. Children and Society, 28, 231–241.CrossRefGoogle Scholar
  25. Breggin, P. (2014b). Guilt, shame and anxiety: Understanding and overcoming negative emotions. Amherst, NY: Perseus Books.Google Scholar
  26. Breggin, P. (2015). The biological evolution of guilt, shame and anxiety: A new theory of negative emotions. Medical Hypotheses. doi:10.1016/j.mehy.2015.03.015.PubMedGoogle Scholar
  27. Breggin, P., & Breggin, G. (2004). Talking back to Prozac. New York: St. Martin’s Press.Google Scholar
  28. Cade, J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 2(36), 349–352.PubMedGoogle Scholar
  29. Caplan, P. (1996). They say you’re crazy: How the world’s most powerful psychiatrists decide who’s normal. New York: De Capo Press.Google Scholar
  30. Caplan, P. (2015). Diagnosisgate: Conflict of interest at the top of the psychiatric apparatus. Aporia, 7(1). Retrieved May 3, 2015 from http://www.madinamerica.com/2015/03/revisiting-tmap-scandal-j-j-paid-allen-frances-develop-schizophrenia-guidelines/.
  31. Corrigan, M. W. (2012). Handbook of prosocial education. Lanham, MD: Roman and Littlefield.Google Scholar
  32. Corrigan, M. W. (2014). Debunking ADHD: 10 reasons to stop drugging kids for acting like kids. Lanham, MD: Roman and Littlefield.Google Scholar
  33. Cosgrove, L. (2010). Diagnosing conflict-of-interest disorder: Big Pharma works in subtle but powerful ways inside the pages of the Diagnostic and Statistical Manual of Mental Disorders. AAUP (American Association of University Professors). Retrieved May 1, 2015 from http://www.aaup.org/article/diagnosing-conflict-interest-disorder#.VUQf-5N4YmQ.
  34. Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 76, 154–160.CrossRefGoogle Scholar
  35. Csoska, A., & Shipko, S. (2006). Persistent sexual side effects after SSRI discontinuation. Psychotherapy and Psychosomatics, 75, 187–188.CrossRefGoogle Scholar
  36. Cuijpers, P., Berking, M., Andersson, G., et al. (2013a). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry, 58(7), 376–385.Google Scholar
  37. Cuijpers, P., Donker, T., van Straten, A., & Andersson, G. (2010). Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychological Medicine, 40, 1943–1957.PubMedCrossRefGoogle Scholar
  38. Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., et al. (2013b). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry, 12, 137–148.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Decker, H. (2013). The Making of DSM-III ® : A diagnostic manual’s conquest of American psychiatry. New York: Oxford University Press.Google Scholar
  40. Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayde & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: Lippincott.Google Scholar
  41. El-Mallakh, R., Gao, Y., & Roberts, J. (2011). Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression. Medical Hypotheses, 76, 769–773.PubMedCrossRefGoogle Scholar
  42. Frances, A. (2014). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis: DSM-5, Big Pharma, and the Medicalization of Ordinary Life. New York: William Morrow.Google Scholar
  43. Gitlin, M., Swendsen, J., Heller, T., & Hammen, C. (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry, 152, 1635–1640.PubMedCrossRefGoogle Scholar
  44. Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster.Google Scholar
  45. Gøtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Medical Press.Google Scholar
  46. Gøtzsche, P. C. (2015). Deadly psychiatry and organised denial. Copenhagen: People’s Press.Google Scholar
  47. Grahame-Smith, D. G., & Aronson, J. K. (1992). Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press.Google Scholar
  48. Harrow, M., & Jobe, T. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A fifteen year multifollow-up study. Journal of Nervous and Mental Disease, 195, 406–414.PubMedGoogle Scholar
  49. Healy, D. (2015). Serotonin and depression: The marketing of a myth. BMJ, 350, h1771. doi:10.1136/bmj.h1771.PubMedCrossRefGoogle Scholar
  50. Insel, T. (2011, December). Director’s Blog: Antidepressants: A complicated picture. Retrieved on May 1, 2015 from http://www.nimh.nih.gov/about/director/2011/antidepressants-a-complicated-picture.shtml.
  51. Janssen Pharmaceuticals, Inc. (2014). Risperdal Complete Prescribing Information. Retrieved on May 1, 2015 from http://www.janssenpharmaceuticalsinc.com by Googling “Risperdal Full Prescribing Information”.
  52. Janssen Research Foundation. (1992a, February). An integrated summary of the effectiveness of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.Google Scholar
  53. Janssen Research Foundation. (1992b, March). Integrated summary of information on the safety of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.Google Scholar
  54. Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 188, 122–127.PubMedCrossRefGoogle Scholar
  55. Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.CrossRefGoogle Scholar
  56. Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56.Google Scholar
  57. Karon, B., & Vandenbos, G. (1981). The psychotherapy of schizophrenia: The treatment of choice. New York: Aronson.Google Scholar
  58. Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. New York: Basic Books.Google Scholar
  59. Kirsch, I., Deacon, B. J., Huedo-Median, T., Scoboria, A., Moore, T., & Johnson, B. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Kutchins, H., & Kirk, S. (2003). Making Us Crazy: DSM: The Psychiatric Bible and the creation of mental disorders. New York: Free Press.Google Scholar
  61. Lacasse, J. R., & Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med, 2(12), e392.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Lagace, D. C., & Eisch, A. J. (2005). Mood-stabilizing drugs: Are their neuroprotective aspects clinically relevant? The Psychiatric Clinics of North America, 28(2), 399–414.PubMedCrossRefGoogle Scholar
  63. Leber, P. (1992). Postmarketing surveillance of adverse drug effects. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs (pp. 3–12). New York: Guilford.Google Scholar
  64. Lehmann, H. E., & Hanrahan, G. C. (1954). Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. Archives of Neurology and Psychiatry, 71, 227–237.PubMedCrossRefGoogle Scholar
  65. Lieberman, J., & Stroup, T. (2011). The NIMH-CATIE schizophrenia study: What did we learn? American Journal of Psychiatry, 168, 770–775.PubMedCrossRefGoogle Scholar
  66. Lieberman, J., Stroup, T., McEvoy, J., Swartz, M., Rosenheck, R., Perkins, D., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMedCrossRefGoogle Scholar
  67. Madsen, T., Treschow, A., Bengzon, J., Bolwig, T., Lindvall, O., & Tingstrom, A. (2000). Increased neurogenesis is a model of electroconvulsive therapy. Biological Psychiatry, 47, 1043–1049.PubMedCrossRefGoogle Scholar
  68. Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience, 20(24), 9104–9110.PubMedGoogle Scholar
  69. Marangell, L., Silver, J., Goff, D., & Yudofsky, S. (2003). Pharmacology and electroconvulsive therapy. In R. Hales & S. Yudofsky (Eds.), The American Psychiatric Publishing textbook of clinical psychiatry (4th ed., pp. 1047–1149). Washington, DC: American Psychiatric Press.Google Scholar
  70. Marks, I. M., De Albuquerque, A., Cottraux, J., Gentil, V., Greist, J., Hand, I., et al. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: A critique of recent reports. Archives of General Psychiatry, 46(7), 668–670.Google Scholar
  71. Miller, R. (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current Neuropharmacology, 7, 315–330.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Hampshire: Palgrave Macmillan.CrossRefGoogle Scholar
  73. Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.CrossRefGoogle Scholar
  74. Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.CrossRefGoogle Scholar
  75. Morrison, A., Hutton, P., Wardle, M., Spencer, H., Barratt, S., Brabban, A., et al. (2012). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial. Psychological Medicine, 42, 1049–1056.PubMedCrossRefGoogle Scholar
  76. Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomized controlled trial. Lancet, 383, 1395–1403.PubMedCrossRefGoogle Scholar
  77. Mosher, L. (1996). Soteria: A therapeutic community for psychotic patients. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York: Haworth Press.Google Scholar
  78. Mosher, L., & Bola, J. (2004). Soteria-California and its American Successors: Therapeutic ingredients. Ethical Human Psychology and Psychiatry, 6, 7–23.Google Scholar
  79. Myslobodsky, M. S. (1993). Central determinants of attention and mood disorder in tardive dyskinesia ("tardive dysmentia"). Brain and Cognition, 23(1), 88–101.PubMedCrossRefGoogle Scholar
  80. Myslobodsky, M. S., Tomer, R., Holden, T., Kempler, S., & Sigal, M. (1985). Cognitive impairment in patients with tardive dyskinesia. The Journal of Nervous and Mental Disease, 173(3), 156–160.PubMedCrossRefGoogle Scholar
  81. Neal, M., Gardner, C., Halberstadt, L., Kornstein, S., & Andrew, P. (2011). Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology, 2011(2), 2011. doi:10.3389/fpsy.g.2011.00159.Google Scholar
  82. Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147–151.Google Scholar
  83. Orser, B. (2007, June). Lifting the fog around anesthesia. Scientific American, pp. 54–59.Google Scholar
  84. Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015.PubMedCrossRefGoogle Scholar
  85. Parent, Jack. (2003). Injury-induced neurogenesis in the adult mammalian brain. The Neuroscientist, 9(4), 261–272.PubMedCrossRefGoogle Scholar
  86. Perlis, R., Ostacher, M., Patel, J., Marangell, L., Zhang, H., Wisniewski, S., et al. (2006). Predictors of recurrent in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 163, 217–224.PubMedCrossRefGoogle Scholar
  87. Pies, R. (2011, July 11). Psychiatry’s new brain-mind and the legend of the “chemical imbalance.” Psychiatric Times. Retrieved on May 1, 2015 from http://www.psychiatrictimes.com/blogs/couch-crisis/psychiatry-new-brain-mind-and-legend-chemical-imbalance.
  88. Pigott, H. (2011). STAR*D: A tale and trail of bias. Ethical Human Psychology and Psychiatry, 13, 6–28.CrossRefGoogle Scholar
  89. Pigott, H., Leventhal, A., Alter, G., & Boren, J. (2011). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79, 267–279.CrossRefGoogle Scholar
  90. Podrabinek, A. (1979). Punitive medicine. In H. Fireside (Ed.), Soviet psychoprisons. New York: Norton.Google Scholar
  91. Randrup, A., & Munkva, I. (1967). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia, 11, 300–310.PubMedCrossRefGoogle Scholar
  92. Read, M. (2002, March 12). Long acting neuroleptic drugs. In D. Heard (Ed.), Zoological Restraint and Anesthesia. International Veterinary Information Service (www.ivis.org), Ithaca, New York. Retrieved on October 25, 2011 from http://www.ivis.org/special_books/Heard/read/IVIS.pdf.
  93. Rothman, D. J. (2010). Expert Report [For the Texas Attorney General’s Office against Johnson and Johnson, and its subsidiary Janssen, the manufacturer of Risperdal]. Unpublished. Retrieved on May 3, 2015 from http://psychrights.org/States/Texas/exrelJonesvJanssen/David_Rothman_Expert_Report_300dpi.pdf.
  94. Schiorring, E. (1977). Changes in individual and social behavior induced by amphetamines and related compounds in monkeys and man. In E. H. Ellinwood Jr & M. M. Kilbey (Eds.), Cocaine and other stimulants (pp. 481–522). New York: Plenum.CrossRefGoogle Scholar
  95. Schiorring, E. (1979). Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology (Berl), 64, 297–302.CrossRefGoogle Scholar
  96. Seikkula, J., Aaltonen, J., Alakare, L., Haarakangas, K., Keranen, J., & Lehtinen, K. (2006). Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research, 16, 214–228.CrossRefGoogle Scholar
  97. Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182.Google Scholar
  98. Swanson, J., Elliott, G., Greenhill, L., Wigal, T., Arnold, L., Vitiello, B., et al. (2007a). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1015–1027.PubMedCrossRefGoogle Scholar
  99. Swanson, J., Hinshaw, S., Arnold, L., Gibbons, R., Marcus, S., Hur, K., et al. (2007b). Second evaluation of MTA 36-month outcomes: Propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 989–1002.PubMedCrossRefGoogle Scholar
  100. Tuke, S. (1996). Description of the retreat. London: Process Press.Google Scholar
  101. University of Rochester Medical Center (2011). Anti-depressants boost brain cells after injury in early studies. Retrieved April 11, 2015 from http://www.urmc.rochester.edu/news/story/index.cfm?id=3173.
  102. Wang, C., Zhang, M., Sun, C., Cai, Y., You, Y., Huang, L., & Liu, F. (2011). Sustained increase in adult neurogenesis in the rat hippocampal dentate gyrus after transient brain ischemia. Neuroscience Letters, 28, 70–75.Google Scholar
  103. Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press.Google Scholar
  104. Weiss, M., Murray, C., Wasdell, M., Greenfield, B., Giles, L., & Hechtman, L. (2012). A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry, 12, 30.PubMedPubMedCentralCrossRefGoogle Scholar
  105. Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. New York: Perseus.Google Scholar
  106. Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of the mental illness in America. New York: Crown Publishers.Google Scholar
  107. Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.CrossRefGoogle Scholar
  108. Wilson, D., & Singer, N. (2009, September 11). Ghostwriting is called rife in medical Journals. New York Times. Retrieved April 5, 2015 from http://www.nytimes.com/2009/09/11/business/11ghost.html?_r=0.
  109. XANAX® XR CIV (alprazolam) extended-release tablets (2011). (Complete Prescribing Information, 22 pages). (2011, March). Retrieved August 31, 2011 from http://labeling.pfizer.com/ShowLabeling.aspx?id=543.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Center for the Study of Empathic TherapyIthacaUSA

Personalised recommendations